Cognitive function in relapsing multiple sclerosis: minimal changes in a 10-year clinical trial - PubMed (original) (raw)
Randomized Controlled Trial
. 2007 Apr 15;255(1-2):57-63.
doi: 10.1016/j.jns.2007.01.070. Epub 2007 Feb 28.
Affiliations
- PMID: 17331542
- DOI: 10.1016/j.jns.2007.01.070
Randomized Controlled Trial
Cognitive function in relapsing multiple sclerosis: minimal changes in a 10-year clinical trial
Steven R Schwid et al. J Neurol Sci. 2007.
Abstract
Background: Although cognitive impairment is common in patients with multiple sclerosis (MS), its value as a clinical trial endpoint remains uncertain. For example, in the randomized, blinded, pivotal trial of glatiramer acetate (GA) in patients with relapsing MS, improvements occurred in neuropsychological test scores during 2 years of treatment regardless of whether patients received GA or placebo, likely due to practice effects.
Objectives: To assess long-term changes in neuropsychological status following 10 years of prospective evaluation in a typical immunotherapy trial cohort.
Methods: Participants in the ongoing open-label GA extension study repeated the Brief Repeatable Battery of Neuropsychological Tests an average of 10.6+/-0.4 years after their initial baseline evaluation.
Results: Mean scores on tests of memory and semantic retrieval were not significantly changed over 10 years of follow-up, but tests of attention showed declines for the group as a whole. Using a threshold of a 0.5 SD decline to define significant worsening, individual tests showed declines in 27-49% of participants and a composite score showed worsening in 19%. Controlling for age, gender, and education level, cognitive tests tended to worsen more in participants with better baseline cognitive test scores and higher EDSS scores. Changes in cognitive test scores during the first 2 years of observation were predictive of 10-year changes.
Conclusions: Most patients with relapsing MS had stable cognitive performance during 10 years of prospective evaluation, some of which may be related to a therapeutic effect of GA. Because cognitive changes occur slowly on average, they may not be responsive enough to serve as useful endpoints in studies of course-modifying therapies in relapsing MS.
Similar articles
- Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.
Patti F, Amato MP, Trojano M, Bastianello S, Tola MR, Goretti B, Caniatti L, Di Monte E, Ferrazza P, Brescia Morra V, Lo Fermo S, Picconi O, Luccichenti G; COGIMUS Study Group. Patti F, et al. Mult Scler. 2009 Jul;15(7):779-88. doi: 10.1177/1352458509105544. Mult Scler. 2009. PMID: 19542262 - Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis.
Patti F, Amato MP, Bastianello S, Caniatti L, Di Monte E, Ferrazza P, Goretti B, Gallo P, Morra VB, Lo Fermo S, Picconi O, Tola MR, Trojano M; COGIMUS Study Group. Patti F, et al. Mult Scler. 2010 Jan;16(1):68-77. doi: 10.1177/1352458509350309. Epub 2009 Dec 7. Mult Scler. 2010. PMID: 19995846 Clinical Trial. - Management of worsening multiple sclerosis with mitoxantrone: a review.
Fox EJ. Fox EJ. Clin Ther. 2006 Apr;28(4):461-74. doi: 10.1016/j.clinthera.2006.04.013. Clin Ther. 2006. PMID: 16750460 Review. - Glatiramer acetate for treatment of relapsing-remitting multiple sclerosis.
Johnson KP. Johnson KP. Expert Rev Neurother. 2012 Apr;12(4):371-84. doi: 10.1586/ern.12.25. Expert Rev Neurother. 2012. PMID: 22449210 Review.
Cited by
- Patients with chronic autoimmune demyelinating polyneuropathies exhibit cognitive deficits which might be associated with CSF evidence of blood-brain barrier disturbance.
Yalachkov Y, Uhlmann V, Bergmann J, Soydaş D, Frisch S, Behrens M, Foerch C, Gehrig J. Yalachkov Y, et al. PLoS One. 2020 Feb 4;15(2):e0228679. doi: 10.1371/journal.pone.0228679. eCollection 2020. PLoS One. 2020. PMID: 32017808 Free PMC article. - Effects of single dose mixed amphetamine salts--extended release on processing speed in multiple sclerosis: a double blind placebo controlled study.
Morrow SA, Rosehart H. Morrow SA, et al. Psychopharmacology (Berl). 2015 Dec;232(23):4253-9. doi: 10.1007/s00213-015-4051-6. Epub 2015 Aug 21. Psychopharmacology (Berl). 2015. PMID: 26289355 Clinical Trial. - BDNF+/- mice exhibit deficits in oligodendrocyte lineage cells of the basal forebrain.
Vondran MW, Clinton-Luke P, Honeywell JZ, Dreyfus CF. Vondran MW, et al. Glia. 2010 May;58(7):848-56. doi: 10.1002/glia.20969. Glia. 2010. PMID: 20091777 Free PMC article. - Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study.
Iaffaldano P, Viterbo RG, Paolicelli D, Lucchese G, Portaccio E, Goretti B, Direnzo V, D'Onghia M, Zoccolella S, Amato MP, Trojano M. Iaffaldano P, et al. PLoS One. 2012;7(4):e35843. doi: 10.1371/journal.pone.0035843. Epub 2012 Apr 25. PLoS One. 2012. PMID: 22558238 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources